Why the seed funding slowdown is a talent problem, not just a funding one.

​Seed capital in life sciences is down 44% year on year, from $851M across 52 deals in H1 2025 to $477M across 46 deals in H1 2026. On its own, that reads as a funding headline. Look at where seed sits in the pipeline, and it's a talent and innovation story that won't show up for another three to five years.

The seed cheque has nearly halved

The average seed cheque fell from $17.3M in Q2 2025 to $8.4M in Q2 2026 , a 51% drop year on year, and 32% smaller than Q1 2026 alone. Deal count barely moved over the same period, down just 2%. The number of companies getting funded has stayed broadly flat. What each of them is receiving has not.

Capital hasn't disappeared, it's moved later

Series B and IPO cheques both grew substantially over the same window: Series B average size up 81% ($61.3M to $110.9M), IPO average size up 104% ($155M to $316M). Total capital raised across the market is up 48% year on year. The money is there. It's concentrated at a later stage, and in fewer, larger bets.

Why the timing matters

A seed round raised in 2026 is, on a typical trajectory, the Series A/B of 2027-28, the IPO or scale-up of 2029-30, and the point at which serious hiring begins shortly after. A thinner seed cohort today points to a thinner pipeline of growth-stage companies, and growth-stage employers, a few years out. The effect of a seed slowdown shows up as a hiring gap before it shows up in a funding report.

Seed stage also does specific work for the sector that later rounds don't replicate. It's typically where a scientist first takes on a founder role, where an early-career hire gets a first "Head of" title, and where early-stage science gets initial backing before it's proven enough for a larger cheque. Fewer seed rounds means less of all three: fewer new founders, fewer early leadership opportunities, and fewer unproven ideas getting a first chance.

What this means for hiring over the next few years

None of this replaces capital, but there are ways life sciences companies can build resilience into their hiring plans while funding conditions recover:

• Hire for the runway available, not the one hoped for. Fractional and interim leadership, a part-time CSO, an interim Head of CMC gives growth-stage teams access to senior expertise without committing to a full-time hire before the business is ready to support one.

• Compete on mission, not just cash. Growth-stage companies are rarely able to match the compensation on offer at later funding stages. Candidates sourced through specialist communities, rather than mainstream platforms alone, are often motivated as much by mission as by comp, BioTalent's network reaches 32% beyond LinkedIn, with access to over 650,000 followers and a database of 2 million-plus qualified candidates across the sector.

• Bring talent planning into diligence, not after the round closes. When investors and talent partners shape the hiring plan alongside the term sheet, headcount is aligned to runway from day one, rather than being resolved reactively once funding is in place.

• Build shared operator pools. Experienced professionals working part-time across two or three growth-stage companies keep specialist expertise circulating through the sector, even where no single business can yet support a full-time role on its own.

BioTalent works with growth-stage life sciences businesses to build hiring plans that reflect this reality, drawing on a global community built specifically to reach candidates who aren't visible through traditional channels alone. In a market where capital is concentrated at fewer, later-stage companies, that access matters more, not less.